Eculizumab Completed Phase 3 Trials for Leukemias Prevention

IndicationsStatusPurposePhase
CompletedPrevention3
clinicaltrials.gov IdentifierTitleDrugs
NCT00112983Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria